Aruna Biomedical
Clinical-stage biotechnology company developing a neural stem cell‑derived exosome platform for central nervous system (CNS) applications. The organization advances a lead therapeutic exosome candidate intended to cross the blood–brain barrier to deliver intrinsic therapeutic cargo and to act as a delivery vehicle for nucleic acids and proteins. Activities include preclinical efficacy and biodistribution studies, an in‑house cGMP manufacturing capability, and regulatory submissions to enable clinical trials.
Industries
Nr. of Employees
small (1-50)
Aruna Biomedical
Products
Neural exosome therapeutic (lead program AB126)
Allogeneic neural stem cell‑derived exosome candidate designed to target CNS cells, cross the blood–brain barrier, provide intrinsic therapeutic activity (anti‑inflammatory, neuroprotective, regenerative) and serve as a delivery vehicle for nucleic acids and proteins.
AB126
Allogenic neural exosomes derived from proprietary non-transformed neural stem cells, designed for CNS applications with the ability to cross the blood-brain barrier and concentrate in brain regions such as the cerebellum and basal ganglia. Used as a therapeutic agent or payload delivery system for siRNA, ASOs, and proteins like monoclonal antibodies.
AB126 therapeutic exosome
AB126 is a therapeutic exosome with CNS specificity, equipped with receptors and surface proteins that allow it to cross the blood-brain barrier and concentrate in the brain, including the cerebellum and basal ganglia.
Neural exosome therapeutic (lead program AB126)
Allogeneic neural stem cell‑derived exosome candidate designed to target CNS cells, cross the blood–brain barrier, provide intrinsic therapeutic activity (anti‑inflammatory, neuroprotective, regenerative) and serve as a delivery vehicle for nucleic acids and proteins.
AB126
Allogenic neural exosomes derived from proprietary non-transformed neural stem cells, designed for CNS applications with the ability to cross the blood-brain barrier and concentrate in brain regions such as the cerebellum and basal ganglia. Used as a therapeutic agent or payload delivery system for siRNA, ASOs, and proteins like monoclonal antibodies.
AB126 therapeutic exosome
AB126 is a therapeutic exosome with CNS specificity, equipped with receptors and surface proteins that allow it to cross the blood-brain barrier and concentrate in the brain, including the cerebellum and basal ganglia.
Services
Collaborative access and development partnerships to apply a neural exosome delivery platform for CNS therapeutic payloads, including provision of manufacturing and preclinical support.
Collaborative access and development partnerships to apply a neural exosome delivery platform for CNS therapeutic payloads, including provision of manufacturing and preclinical support.
Expertise Areas
- Exosome-based therapeutics
- CNS drug delivery across the blood–brain barrier
- Preclinical translational stroke and CNS models
- cGMP biologics manufacturing and scale-up
Key Technologies
- Extracellular vesicles / exosomes
- Tangential flow filtration (TFF)
- Chromatography for biologics purification
- Imaging flow cytometry
News & Updates
Pre-recorded corporate presentation made available beginning November 22, 2021.
Announcement of FDA clearance of an IND enabling the lead neural exosome program to enter human clinical trials for a neurological indication.
Announcement of a U.S. patent covering composition of matter for neural exosomes intended for delivery of therapeutics to the brain.
Announcement of a U.S. patent for a method of use for neural exosomes to reduce inflammation in the brain.
Publication reporting improved tissue and functional recovery after neural stem cell extracellular vesicle treatment in a porcine model of ischemic stroke (Stroke, 2018).
Pre-recorded corporate presentation made available beginning November 22, 2021.
Announcement of FDA clearance of an IND enabling the lead neural exosome program to enter human clinical trials for a neurological indication.
Announcement of a U.S. patent covering composition of matter for neural exosomes intended for delivery of therapeutics to the brain.
Announcement of a U.S. patent for a method of use for neural exosomes to reduce inflammation in the brain.
Publication reporting improved tissue and functional recovery after neural stem cell extracellular vesicle treatment in a porcine model of ischemic stroke (Stroke, 2018).